Denali Therapeutics (DNLI) EPS (Basic) (2017 - 2024)
Historic EPS (Basic) for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$0.7.
- Denali Therapeutics' EPS (Basic) rose 1985.24% to -$0.7 in Q4 2024 from the same period last year, while for Sep 2025 it was -$0.67, marking a year-over-year increase of 7363.39%. This contributed to the annual value of -$2.57 for FY2024, which is 14249.61% down from last year.
- Denali Therapeutics' EPS (Basic) amounted to -$0.7 in Q4 2024, which was up 1985.24% from -$0.63 recorded in Q3 2024.
- Over the past 5 years, Denali Therapeutics' EPS (Basic) peaked at $2.3 during Q4 2020, and registered a low of -$0.87 during Q4 2023.
- Its 5-year average for EPS (Basic) is -$0.4, with a median of -$0.6 in 2021.
- As far as peak fluctuations go, Denali Therapeutics' EPS (Basic) skyrocketed by 50703.17% in 2020, and later crashed by 14377.15% in 2024.
- Denali Therapeutics' EPS (Basic) (Quarter) stood at $2.3 in 2020, then tumbled by 126.96% to -$0.62 in 2021, then dropped by 20.97% to -$0.75 in 2022, then decreased by 16.0% to -$0.87 in 2023, then rose by 19.85% to -$0.7 in 2024.
- Its EPS (Basic) was -$0.7 in Q4 2024, compared to -$0.63 in Q3 2024 and -$0.59 in Q2 2024.